As of 2025-12-15, the Intrinsic Value of Neoleukin Therapeutics Inc (NLTX) is -18.23 USD. This NLTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 3.49 USD, the upside of Neoleukin Therapeutics Inc is -622.31%.
Based on its market price of 3.49 USD and our intrinsic valuation, Neoleukin Therapeutics Inc (NLTX) is overvalued by 622.31%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -18.23 - -18.23 | -18.23 | -622.31% |
| P/E | (27.42) - (51.11) | (37.73) | -1181.2% |
| DDM - Stable | (24.85) - (67.22) | (46.03) | -1419.1% |
| DDM - Multi | (37.94) - (80.88) | (51.76) | -1583.2% |
| Market Cap (mil) | 32.81 |
| Beta | -0.35 |
| Outstanding shares (mil) | 9.40 |
| Enterprise Value (mil) | 7.61 |
| Market risk premium | 5.00% |
| Cost of Equity | 11.58% |
| Cost of Debt | 5.00% |
| WACC | 11.48% |